Search “CJC peptide” and you’ll run into a naming mess almost immediately: CJC-1295, CJC-1295 without DAC, CJC-1293, Mod GRF 1-29 — sometimes all described as if they’re the same thing, sometimes treated as entirely different compounds, depending on which vendor or forum you’re reading. Some of that confusion is genuine ambiguity in how the industry uses these names; some of it is sloppy or misleading labeling by sellers who aren’t being precise about what’s actually in the vial.
This guide sorts out what “CJC peptide” actually refers to, how the different named variants relate to each other, how CJC-1295 compares to the peptides it’s most often paired or compared with, and what matters most if you’re trying to understand this category before looking into it further.
What Does “CJC Peptide” Actually Mean?
In almost all cases, “CJC peptide” is shorthand for CJC-1295, a synthetic analog of growth hormone-releasing hormone (GHRH) developed by the Canadian biotech company ConjuChem — which is where the “CJC” prefix comes from. It’s part of a broader category of compounds designed to stimulate the pituitary gland to release growth hormone, rather than introducing growth hormone directly the way HGH injections do.
The confusion starts because CJC-1295 isn’t really one single product — it’s a name that gets applied, sometimes accurately and sometimes not, to a few related but distinct molecules.
Untangling the CJC-1295 Family
CJC-1295 with DAC is the original ConjuChem compound as developed and studied in clinical trials. The “DAC” stands for Drug Affinity Complex, a modification that allows the peptide to bind to albumin in the blood, dramatically extending its activity. This is the version responsible for CJC-1295’s reputation for long-lasting effects, with a single dose remaining active for roughly a week.
CJC-1295 without DAC is where the naming gets genuinely murky. Technically, removing the DAC modification from CJC-1295 doesn’t leave you with a smaller version of the same compound — it leaves you with a different, shorter-acting peptide that’s more accurately called Modified GRF (1-29). Many vendors sell this under the “CJC-1295 without DAC” label anyway, since it’s built from the same core GHRH(1-29) sequence, but it behaves quite differently in practice: instead of sustaining GH elevation for days, it produces a sharp, brief pulse lasting under an hour, requiring far more frequent dosing.
CJC-1293 is an earlier, related analog that predates CJC-1295, differing by a single amino acid substitution. It’s sometimes confused with or mislabeled as “CJC-1295 without DAC” by sellers, even though it’s technically a distinct molecule with its own history. If you see both names used interchangeably by the same vendor, that’s a reasonable signal to ask specifically which compound you’re actually being sold, since precision here isn’t just academic — it affects dosing and expected duration of effect.
Sermorelin (GRF 1-29) is the unmodified original sequence that all of these compounds are derivatives of. It has its own separate regulatory history — including a prior FDA approval that CJC-1295 never had — which is worth knowing if you’re comparing options.
The practical takeaway: if you’re looking at a product labeled simply “CJC peptide” or “CJC-1295,” it’s worth confirming specifically whether it’s the DAC or non-DAC version, since these behave differently enough that the distinction matters for anyone trying to understand what they’re actually being offered.
How CJC-1295 Compares to Peptides It’s Often Paired With
CJC-1295 and ipamorelin are frequently discussed together as a “stack,” and the logic behind pairing them is straightforward: CJC-1295 works through the GHRH receptor pathway to sustain elevated growth hormone signaling, while ipamorelin works through a different pathway — the ghrelin receptor — to trigger a more immediate GH pulse. The combination is popular specifically because the two mechanisms are complementary rather than redundant, though it’s worth being clear-eyed that there isn’t strong, high-quality long-term data confirming that using them together is more effective or safer than either compound alone.
CJC-1295 and tesamorelin work through a similar general mechanism — both are GHRH analogs — but tesamorelin has something CJC-1295 doesn’t: FDA approval, specifically for reducing excess abdominal fat in people with HIV-associated lipodystrophy. That approval doesn’t mean tesamorelin is interchangeable with CJC-1295 for other goals, but it does mean there’s a meaningfully larger body of formal clinical trial data behind it, which is worth factoring in if you’re comparing the two.
What CJC-1295 Is Actually Used For
Across clinics and wellness protocols, CJC-1295 is most commonly discussed in the context of body composition support, recovery, sleep quality, and general anti-aging goals — all connected to its effect of raising growth hormone and, downstream, IGF-1 levels.
It’s worth being direct about the evidence gap here: while the underlying GHRH mechanism is well-established science, and CJC-1295’s early-stage human trial showed it does raise GH and IGF-1 as intended, there isn’t robust, large-scale clinical trial data specifically confirming the body composition, energy, or anti-aging outcomes it’s commonly marketed for in adult wellness settings. That’s a different claim than saying it doesn’t work — it means the specific outcome claims run ahead of what’s been rigorously studied, which is worth factoring into realistic expectations.
Regulatory Status: A Brief Note
CJC-1295’s legal standing for compounding pharmacy access has been genuinely unsettled and subject to change since late 2023, when it was placed on the FDA’s restricted “Category 2” compounding list. That status has shifted more than once since, and reporting on its current position has been inconsistent even among recent sources. Rather than repeat a specific claim here that could be outdated by the time you’re reading this, the more useful guidance is this: if you’re considering CJC-1295 specifically, confirm its current compounding status directly with the FDA’s bulk drug substances list or a licensed provider, since this is one of the more actively changing corners of peptide regulation right now.
Sourcing: Where the Real Risk Lives
Regardless of which specific CJC compound you’re looking at, or where its regulatory status currently sits, the biggest practical risk in this category isn’t the molecule itself — it’s how it’s obtained.
A legitimate path involves a licensed physician evaluating whether a GHRH-pathway peptide fits your health profile, and, where currently permitted, a licensed compounding pharmacy preparing it under regulatory oversight, typically alongside baseline and follow-up lab monitoring.
“Research chemical” sourcing, common for CJC-1295 and its variants given the compound’s regulatory history, involves none of that. These products are sold with “not for human consumption” disclaimers precisely to sidestep the oversight that would otherwise apply, and independent testing of peptides sold this way has repeatedly found contamination, incorrect concentrations, and outright mislabeling — including, specifically in this category, confusion between CJC-1295, CJC-1293, and Mod GRF 1-29 being sold under whichever name the vendor thinks will sell better.
Frequently Asked Questions
Is “CJC peptide” the same as CJC-1295? In almost all everyday use, yes — “CJC peptide” is informal shorthand for CJC-1295, though it’s worth confirming which specific variant (with or without DAC) is being discussed, since they behave quite differently.
What’s the actual difference between CJC-1295 and CJC-1293? They’re closely related GHRH analogs differing by a single amino acid substitution, with CJC-1293 predating CJC-1295. They’re sometimes confused or mislabeled interchangeably by sellers, which makes confirming exactly which compound you’re looking at worthwhile if the distinction matters to you.
Is CJC-1295 without DAC the same thing as Mod GRF 1-29? Functionally, yes — “CJC-1295 without DAC” is a marketing label commonly applied to what’s more precisely called Modified GRF (1-29), a short-acting peptide that behaves quite differently from CJC-1295 with DAC despite the shared naming.
Why is CJC-1295 often paired with ipamorelin? The two work through different mechanisms — CJC-1295 through the GHRH receptor pathway and ipamorelin through the ghrelin receptor pathway — which is thought to produce a stronger combined effect on growth hormone release than either alone, though robust long-term safety and efficacy data on the combination specifically is limited.
Is CJC-1295 FDA-approved? No. CJC-1295 has never received FDA approval for any indication, unlike sermorelin, which briefly held approval for a diagnostic use, or tesamorelin, which remains FDA-approved for a specific fat-reduction indication. Its availability depends on current compounding regulations, which have changed multiple times in recent years.
Key Takeaways
“CJC peptide” is a simple-sounding term that hides a fair amount of genuine naming confusion, and much of that confusion works in favor of vendors who aren’t being precise about what they’re actually selling. Understanding the real distinctions — DAC versus non-DAC, CJC-1295 versus CJC-1293, and how CJC-1295 compares to related compounds like tesamorelin — puts you in a much better position to ask the right questions, whichever direction you decide to go.
For a deeper look at CJC-1295’s specific regulatory history and safety data, see our full CJC-1295 guide. If you’re considering any peptide in this family, a conversation with a licensed physician who can confirm current rules and evaluate your health history is a more reliable next step than piecing together vendor marketing claims.